Background: Transient epileptic amnesia (TEA) is a rare phenomenon in temporal lobe epilepsy that is often unrecognized or misdiagnosed as transient global amnesia (TGA). It is postulated that TEA is due to both ictal and postictal disturbances. Response to antiseizure medication underlines its epileptic nature. In view of the increasing incidence of new-onset epilepsies in old age, an increase in TEA can be expected in the future.
Objective: Analysis of TEA features in a monocentric case series.
Material And Methods: A search in our electronic patient data base yielded 10 patients with TEA out of 7899 patients over a period of 8 years. Clinical and paraclinical features as well as findings of additional examinations were retrospectively collected. Data are given as mean ± SD.
Results: All 10 patients were diagnosed with temporal lobe epilepsy. The mean age at manifestation of TEA was 59.1 ± 6.7 years, the diagnosis was made with a delay of 21.9 ± 26.3 months. The TEA lasted on average 56 ± 37 min, and 16 ± 9.9 TEA episodes per year were reported by the patients; out of the 10 patients 6 reported that TEA usually occurred upon awakening. In 9 of 10 patients, there was evidence of typical seizure symptoms or other semiological elements during TEA. Interictal neuropsychological disturbances of temporal functions were seen in 8 of 10 patients and evidence of depressive disorder in 6 of 10 patients. Video EEG recordings revealed epileptiform activity during sleep in 4 patients over the left and in 2 patients over both temporal regions. In 3 patients, magnetic resonance imaging displayed typical alterations of the temporomesial structures (in 2 patients on the left and in 1 the right side). Antiseizure medication improved seizure control in 7 of 10 patients (seizure freedom in 6 patients), 3 patients were lost to follow-up.
Discussion: TEA is rare, occurs in older adults and is correctly diagnosed after about 2 years. Thorough assessment of additional symptoms and circumstances, the recurrent occurrence as well as typical EEG and imaging findings of temporal lobe epilepsy enables the distinction between TEA and TGA.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718864 | PMC |
http://dx.doi.org/10.1007/s00115-022-01364-5 | DOI Listing |
Alzheimers Dement
December 2024
Imperial College London, London, United Kingdom; Division of Neurology, Department of Brain Sciences, Imperial College London, United Kingdom, London, London, United Kingdom.
Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue licensed for the treatment of type 2 diabetes mellitus (T2DM). Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells.
Method: This is a multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild to moderate Alzheimer's dementia, conducted at several centres in the UK.
Alzheimers Dement
December 2024
University Hospital RWTH Aachen, Aachen, NRW, Germany.
Background: Physical exercise presents a viable low-cost, low-risk, individual, and widely available non-pharmacological treatment candidate in cognitive decline such as in Alzheimer's disease (AD). There are even indications that it can reduce the risk of developing dementia in the first place (Livingston et al., The Lancet, 2020).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Background: Social health factors have been robustly associated with better cognitive health in older adults; however, less is known about how social network size affects the relationship between in-vivo biomarkers of Alzheimer's disease (AD) pathology and brain aging outcomes. We examined the independent and interactive relationships between plasma pTau181 and social network size on memory function and medial temporal lobe (MTL) volume in older adults.
Method: Participants were 58 community-dwelling older adults (mean age = 75.
Alzheimers Dement
December 2024
Alzheimer's Disease Neuroimaging Initiative, http://adni.loni.usc.edu/, CA, USA.
Background: Several studies have shown that financial capacity constitutes a vital component of instrumental activities of daily living. However, there is insufficient research investigating the relationship between financial impairment, brain volume changes and cognitive decline in Alzheimer's disease (AD). Here, we examine the association between brain volume changes and financial capacity in cognitively unimpaired (CU) and mild cognitively impaired (MCI) individuals.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Ontario Shores Centre for Mental Health Sciences, Whitby, ON, Canada.
Introduction: Leucine-rich glioma-inactivated 1 (LGI-1) antibody encephalitis is a rare subtype of autoimmune limb encephalitis (ALE), which is marked by rapid neuropsychiatric decline. This report details a comprehensive approach to its diagnosis and management.
Assessment: In this case, a 68-year-old man presented with aggressive behaviors, cognitive decline, and seizure-like episodes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!